Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Privigen

Known as: Venimmune 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AIM A pharmacoeconomic analysis of direct costs on treatment with high dose intravenous immunoglobulins (IVIG) and plasmapheresis… Expand
2014
2014
Activated clotting factor FXI (FXIa) has been postulated to play a significant role in thromboembolic events potentially… Expand
2014
2014
IntroductionHemolysis is considered a class effect and a rare adverse event that can occur following therapy with human normal… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2014
2014
High dose intravenous immunoglobulin (IVIG) is an established treatment for various neuromuscular disorders. Recently, cases of… Expand
2014
2014
PurposeThis retrospective study evaluated the effectiveness and tolerability in clinical practice of an L-proline–stabilized 10… Expand
  • table I
  • table II
  • table III
  • figure 1
  • figure 2
Highly Cited
2013
Highly Cited
2013
This prospective, multicenter, single‐arm, open‐label Phase III study aimed to evaluate the efficacy and safety of Privigen® (10… Expand
2009
2009
Abstract Intravenous immunoglobulin (IVIG) has become a mainstay of treatment for acute and chronic immune thrombocytopenic… Expand
2009
2009
The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen… Expand
2009
2009
2009
Background and Objectives  IgPro10 (Privigen©) is a new liquid intravenous immunoglobulin (IVIG) product that is formulated with… Expand